Malignancies Following Lung Transplantation (Q37867766)

24 August 2017

1 reference

title

Malignancies Following Lung Transplantation (English)

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

30 November 2024

1 reference

Hilary Y. Robbins

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21511094

30 November 2024

Selim M. Arcasoy

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21511094

30 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21511094

30 November 2024

publication date

22 March 2011

1 reference

full work available at URL

24 August 2017

https://api.elsevier.com/content/article/PII:S0272523111000256?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

https://api.elsevier.com/content/article/PII:S0272523111000256?httpAccept=text/plain

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Clinics in Chest Medicine

30 November 2024

published in

1 reference

24 August 2017

volume

32

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

343-355

1 reference

Cancer risk following organ transplantation: a nationwide cohort study in Sweden

24 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Incidence of skin cancer in 5356 patients following organ transplantation

30 November 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Identifying High Risk Groups and Quantifying Absolute Risk of Cancer After Kidney Transplantation: A Cohort Study of 15 183 Recipients

30 November 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Posttransplant malignancies

30 November 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Skin Cancer Risk Among Solid Organ Recipients: A Nationwide Cohort Study in Denmark

30 November 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Lymphomas after solid organ transplantation: a collaborative transplant study report

30 November 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

A population-based study of skin cancer incidence and prevalence in renal transplant recipients

30 November 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Cancer after kidney transplantation in the United States

30 November 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Clinicopathologic features of skin cancer in organ transplant recipients: a retrospective case-control series.

30 November 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report--2010.

30 November 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients

30 November 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

30 November 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

30 November 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

mTOR pathway and mTOR inhibitors as agents for cancer therapy

30 November 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

30 November 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

30 November 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab.

30 November 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Azathioprine and UVA light generate mutagenic oxidative DNA damage

30 November 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients

30 November 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia

30 November 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens

30 November 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma

30 November 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Clonal integration of a polyomavirus in human Merkel cell carcinoma

30 November 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens

30 November 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Organ transplant recipients and skin cancer: assessment of risk factors with focus on sun exposure

30 November 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Malignancy after heart transplantation: incidence, prognosis and risk factors.

30 November 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Melanoma in solid organ transplant recipients

30 November 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Malignant melanoma in organ allograft recipients

30 November 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases.

30 November 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Outcomes of melanoma in recipients of solid organ transplant

30 November 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Incidence of skin cancer after renal transplantation in The Netherlands.

30 November 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Guidelines for the management of squamous cell carcinoma in organ transplant recipients

30 November 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patient

30 November 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses

30 November 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy.

30 November 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study

30 November 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

The National Comprehensive Cancer Network (NCCN) guidelines of care for nonmelanoma skin cancers

30 November 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Guidelines for the management of basal cell carcinoma

30 November 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

30 November 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection

30 November 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Role of radiotherapy in the management of organ transplant recipients diagnosed with non-melanoma skin cancers

30 November 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice

30 November 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Recent advances in head and neck cancer

30 November 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab.

30 November 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study

30 November 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients

30 November 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study

30 November 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy

30 November 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial

30 November 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression.

30 November 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Aggressive Behavior of Nonmelanotic Skin Cancers in Solid Organ Transplant Recipients

30 November 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Skin cancer following transplantation: the Israel Penn International Transplant Tumor Registry experience

30 November 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study

30 November 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Skin cancers after organ transplantation

30 November 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

30 November 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection

30 November 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease?

30 November 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.1

30 November 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients

30 November 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient

30 November 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations

30 November 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression

30 November 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation

30 November 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients

30 November 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission

30 November 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk

30 November 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Epstein-Barr virus infection

30 November 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients

30 November 2024

74

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University

30 November 2024

75

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group

30 November 2024

76

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Post-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival

30 November 2024

77

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients

30 November 2024

78

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Early onset post-transplant lymphoproliferative disease is associated with allograft localization.

30 November 2024

79

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Chest radiography as a predictor of outcome in posttransplantation lymphoproliferative disorder in lung allograft recipients

30 November 2024

80

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases

30 November 2024

81

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines.

30 November 2024

82

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients

30 November 2024

83

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease

30 November 2024

84

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction

30 November 2024

85

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Epstein-Barr virus and lymphoproliferative disorders after transplantation

30 November 2024

86

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial.

30 November 2024

87

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients.

30 November 2024

88

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy

30 November 2024

89

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients

30 November 2024

90

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines.

30 November 2024

91

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

30 November 2024

92

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.

30 November 2024

93

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.

30 November 2024

94

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients

30 November 2024

95

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders

30 November 2024

96

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate

30 November 2024

97

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Posttransplant lymphoproliferative disorder: significance of central nervous system involvement

30 November 2024

98

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report

30 November 2024

99

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.

30 November 2024

100

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Anti-CD20 monoclonal antibody therapy in Epstein-Barr Virus-associated B cell lymphoma following lung transplantation

30 November 2024

101

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

30 November 2024

102

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease

30 November 2024

103

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

The management of posttransplant lymphoproliferative disorder

30 November 2024

104

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Treatment of PTLD with rituximab or chemotherapy

30 November 2024

105

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience

30 November 2024

106

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

30 November 2024

107

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

30 November 2024

109

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Risk factors and outcomes for the development of malignancy in lung and heart-lung transplant recipients

30 November 2024

110

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis

30 November 2024

111

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Bronchogenic carcinoma after solid organ transplantation

30 November 2024

112

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Prevalence of Malignancies After Lung Transplantation

30 November 2024

113

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Bronchogenic carcinoma complicating lung transplantation

30 November 2024

114

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Primary bronchogenic carcinoma after heart or lung transplantation: radiologic and clinical findings

30 November 2024

115

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Complications (excluding hyperinflation) involving the native lung after single-lung transplantation: incidence, radiologic features, and clinical importance

30 November 2024

116

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Pulmonary nodules and masses after lung and heart-lung transplantation

30 November 2024

117

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Bronchogenic carcinoma in lung transplant recipients

30 November 2024

118

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Bronchogenic carcinoma after lung transplantation: frequency, clinical characteristics, and imaging findings.

30 November 2024

119

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Bronchogenic carcinoma after lung transplantation: characteristics and outcomes

30 November 2024

120

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Tobacco smoking and cancer: a brief review of recent epidemiological evidence

30 November 2024

121

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

The risk of death by age, sex, and smoking status in the United States: putting health risks in context

30 November 2024

122

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study

30 November 2024

123

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Chronic Obstructive Pulmonary Disease Is Associated with Lung Cancer Mortality in a Prospective Study of Never Smokers

30 November 2024

124

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

High frequency of bronchogenic carcinoma after single-lung transplantation

30 November 2024

125

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Incidence of primary neoplasms in explanted lungs: long-term follow-up from 214 lung transplant patients

30 November 2024

126

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Role of lung transplantation in the treatment of bronchogenic carcinomas for patients with end-stage pulmonary disease.

30 November 2024

127

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Small-cell lung carcinoma of recipient origin after bilateral lung transplantation for cystic fibrosis

30 November 2024

128

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Donor-acquired small cell lung cancer following pulmonary transplantation

30 November 2024

129

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Non–Small Cell Lung Cancer

30 November 2024

131

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Recurrence of bronchioloalveolar carcinoma in transplanted lungs

30 November 2024

132

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

Recurrence of bronchioloalveolar carcinoma in donor lung after lung transplantation: microsatellite analysis demonstrates a recipient origin

30 November 2024

133

1 reference

https://api.crossref.org/works/10.1016/J.CCM.2011.02.011

30 November 2024

Identifiers

1 reference

24 August 2017

1 reference